All Stories

  1. Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease
  2. Primary pulmonary chondrosarcoma: clinical case and review of the literature
  3. Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review
  4. The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery
  5. Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
  6. Global initiative for chronic obstructive lung disease (GOLD) recommendations: strengths and concerns for future needs
  7. Lung Metastatectomy: Can Laser-Assisted Surgery Make a Difference?
  8. Can Chest Ultrasound Replace Chest X-ray in Thoracic Surgery?
  9. RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response
  10. Blood eosinophils in COPD: friend or foe?
  11. Updated simplified approach of pharmacological treatment of stable COPD: Do common co-morbidities have a role?
  12. Depression Levels Influence the Rate of Asthma Exacerbations in Females
  13. Device use errors among patients with asthma and COPD and the role of training: a real-life study
  14. Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature
  15. PROMS and FEV1 as predictors of AECOPD
  16. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study
  17. Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?
  18. Pharmacological treatment of stable COPD: need for a simplified approach
  19. Asthma‐chronic obstructive pulmonary disease overlap: Diagnostic stability and inflammatory characteristics
  20. Inflammatory profile in optimally treated patients with adult versus early-onset asthma
  21. TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients
  22. Mycophenalate Mofetil as a corticosteroid- sparing agent in patients with sarcoidosis.
  23. The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)
  24. Late onset asthma: A distinct phenotype
  25. Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation
  26. Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study
  27. Decreased Serum Sirtuin-1 in COPD
  28. Serum periostin in patients hospitalized for COPD exacerbations
  29. Activin A and follistatin in patients with asthma. Does severity make the difference?
  30. Sputum interleukin‐13 as a biomarker for the evaluation of asthma control
  31. Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
  32. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic asthma
  33. Predictors of future exacerbation risk in patients with asthma
  34. Sputum interleukin-13 as a biomarker for the evaluation of asthma control
  35. Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype
  36. Predictors of exacerbations in asthma
  37. Activin-A BAL levels and Immunochemistry for activin A receptors in patients with asthma
  38. Periostin as a biomarker in patients with asthma: Associations with eosinophilia and Th2 response
  39. Serum periostin in patients hospitalized for COPD exacerbations
  40. Pulmonary alveolar proteinosis: time to shift?
  41. Sputum interleukin (IL)-13 as a biomarker for the evaluation of asthma control
  42. Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma
  43. Increased Levels of Osteopontin in Sputum Supernatant in Patients With COPD
  44. Long-Term Inhaled Granulocyte Macrophage–Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, Safety, and Lowest Effective Dose
  45. Levels of prostaglandin E2 and Cysteinyl‐leukotrienes in sputum supernatant of patients with asthma: the effect of smoking
  46. Noninvasive evaluation of airway inflammation in patients with severe asthma